Kronos Bio Yönetim

Yönetim kriter kontrolleri 2/4

Kronos Bio CEO'su Norbert Bischofberger, Aug2018 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 1.76M olup, şirket hissesi ve opsiyonları dahil olmak üzere 32.9% maaş ve 67.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 21.03% ine doğrudan sahiptir ve bu hisseler $ 11.10M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 5.4 yıldır.

Anahtar bilgiler

Norbert Bischofberger

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi32.9%
CEO görev süresi6.3yrs
CEO sahipliği21.0%
Yönetim ortalama görev süresi1.6yrs
Yönetim Kurulu ortalama görev süresi5.4yrs

Son yönetim güncellemeleri

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Recent updates

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Jun 05

Kronos Bio: Underestimated Drug Discovery Platform

May 06

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jan 19
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Aug 21
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Feb 22
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Nov 01
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Aug 16

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jul 07
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Feb 01
We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Mar 03
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Jan 09
Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Kronos Bio  EPS misses by $4.10

Nov 18

CEO Tazminat Analizi

Norbert Bischofberger'un ücretlendirmesi Kronos Bio'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$86m

Jun 30 2024n/an/a

-US$103m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$580k

-US$113m

Sep 30 2023n/an/a

-US$119m

Jun 30 2023n/an/a

-US$120m

Mar 31 2023n/an/a

-US$123m

Dec 31 2022US$3mUS$580k

-US$133m

Sep 30 2022n/an/a

-US$164m

Jun 30 2022n/an/a

-US$165m

Mar 31 2022n/an/a

-US$161m

Dec 31 2021US$645kUS$320k

-US$151m

Sep 30 2021n/an/a

-US$122m

Jun 30 2021n/an/a

-US$128m

Mar 31 2021n/an/a

-US$108m

Dec 31 2020US$15mUS$399k

-US$88m

Sep 30 2020n/an/a

-US$61m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$280kUS$200k

-US$16m

Tazminat ve Piyasa: Norbert 'nin toplam tazminatı ($USD 1.76M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.28K ).

Tazminat ve Kazançlar: Norbert 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Norbert Bischofberger (68 yo)

6.3yrs

Görev süresi

US$1,761,537

Tazminat

Dr. Norbert W. Bischofberger, Ph D., is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He has been an Independent Director of Morphic Holding, Inc. since June 14, 2019.Dr. Bischofberge...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Norbert Bischofberger
President6.3yrsUS$1.76m21.03%
$ 11.1m
Joshua Kazam
Co-Founder & Directorno dataUS$74.80k0.61%
$ 320.7k
David Tanen
Secretary & Directorno dataUS$74.80k1.52%
$ 799.5k
Deborah Knobelman
COO & CFOless than a yearVeri yok0.27%
$ 143.7k
Charles Lin
Chief Scientific Officerless than a yearVeri yok0.39%
$ 205.3k
Allison Frisbee
Chief Administrative Officerless than a yearVeri yok0.34%
$ 178.9k
Margaux Bennett
Vice President of Corporate Development & Investor Relations3.5yrsVeri yokVeri yok
Elizabeth Olek
Senior Vice President of Clinical Development2.8yrsVeri yok0.32%
$ 169.1k
Wes Trotter
Senior Vice President of Drug Discovery & Pharmaceutical Development1.6yrsVeri yokVeri yok

1.6yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: KRON 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Norbert Bischofberger
President6.6yrsUS$1.76m21.03%
$ 11.1m
Joshua Kazam
Co-Founder & Director7.4yrsUS$74.80k0.61%
$ 320.7k
David Tanen
Secretary & Director7.4yrsUS$74.80k1.52%
$ 799.5k
Owen Witte
Scientific Advisory Board Chairmanno dataVeri yokVeri yok
Arie Belldegrun
Independent Chairman of the Board7yrsUS$117.20k1.13%
$ 594.6k
Elena Ridloff
Independent Director4.2yrsUS$89.17k0.042%
$ 22.1k
Taiyin Yang
Independent Director3.7yrsUS$88.70k0.019%
$ 9.9k
Roshawn Blunt
Independent Director3yrsUS$79.80k0%
$ 0
Angela Koehler
Scientific Advisory Board Memberno dataVeri yokVeri yok
Robert Eisenman
Scientific Advisory Board Memberno dataVeri yokVeri yok
Myles Brown
Scientific Advisory Board Memberno dataVeri yokVeri yok
Katherine Stultz
Independent Director1.7yrsUS$105.68k0%
$ 0

5.4yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KRON 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).